“ú–{ˆã‰È‘åŠwˆãŠw‰ïŽGŽ Online Journal ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚ð”ò‚΂·
‘–ÚŽŸ > †–ÚŽŸ > Abstract ƒz[ƒ€‚Ö–ß‚é
Abstract

‘æ8Šª 2012”N12ŒŽ@‘æ4†

‘S•¶PDF (234K)

¡˜_à

‚ª‚ñŽ¡—ÂƊɘaƒPƒAi4j\•ªŽq•W“IŽ¡—Öò‚Ì–òÜŒoÏ•ªÍ
ˆî–с@r‰î, ˆÉ¨@—Y–ç, •ÐŽR@Žu˜Y
“ú–{ˆã‰È‘åŠw•t‘®•a‰@–òÜ•”

Treatment of Cancer and Palliative Care (4) Cost-effectiveness Analysis of Molecularly Targeted Drugs
Shunsuke Inage, Yuya Ise and Shirou Katayama
Department of Pharmaceutical Service, Nippon Medical School

Various molecularly targeted drugs are now in clinical use in Japan. These agents are generally more effective than previous drugs but are more expensive. Several recent studies have examined the cost-effectiveness of using molecularly targeted drugs in cancer treatment. Herein, we discuss reports about the use of trastuzumab for early-stage breast cancer, lapatinib for advanced breast cancer, and bevacizumab for advanced non-small cell lung cancer.

“úˆã‘åˆã‰ïŽ 2012; 8(4), 241-245

Key words
cost-effectiveness analysis, pharmacoeconomics, molecularly targeted drugs, treatment of cancer

Correspondence to
Shunsuke Inage, Department of Pharmaceutical Service, Nippon Medical School Hospital, 1-1-5 Sendagi, Bunkyo-ku Tokyo 113-8603, Japan
E-mailFshunsukeinage@nms.ac.jp

Žó•tF2012”N4ŒŽ6“ú@Žó—F2012”N7ŒŽ24“ú

ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚Ö–ß‚é ‚±‚̃y[ƒW‚̃gƒbƒv‚Ö–ß‚é